Quick Read Pfizer (PFE) trades at $26.18 with a 24/7 Wall St. price target of $32.92, implying 25.76% upside, driven by ...

Pfizer (NYSE:PFE) has entered a global oncology partnership with Innovent Biologics worth up to $10.5b, focused on up to 12 ...

Pfizer is an over-100-year-old drug company going through a rough patch, which has happened before.

Pfizer PFE has reached a significant support level, making it an attractive option for investors from a technical standpoint. Since the end of May, the stock has been trading above its 50-day simple ...

As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the ...

Last year, Pfizer invested around $9 billion in M&A deals, including the acquisition of Metsera and the licensing deal with ...

Pfizer (NYSE:PFE) shares traded in the red on Monday, making it the seventh consecutive day of losses. The stock closed down 0.35% at $28.45. PFE stock fell about 20.5% in the last 12 months. YTD, the ...

The absence of insider selling at Pfizer (PFE) after a sizable one-year rally is a data point retail investors should be weighing. The signal reflects the steady hand of professionals who see the ...

Pfizer (PFE) announced early Monday that it is halting a late-stage trial of its GLP-1 pill candidate, danuglipron, dashing hopes of the company entering the obesity space in the near term. A trial ...

Pfizer is consolidating at a long-term high, and one investor is buying more time for the stock to break out. optionMONSTER's Heat Seeker monitoring system detected the purchase of about 30,000 ...